ฝัง
- เผยแพร่เมื่อ 22 พ.ค. 2023
- Dr Akeet Bhatt joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.
This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the impact effects of dapagliflozin health status across the full spectrum of LVEF.
Results suggest that dapagliflozin improved health status as measured by KCCQ scores at both 4 and 8 months post-randomization. These improvements were consistently observed across the full spectrum of LVEF.
Interview Questions:
-What was the reasoning behind comparing the DAPA-HF and DELIVER Trials?
-What is the current landscape of research into dapagliflozin in 2023?
-What was the study design and patient cohort?
-What are the key findings?
-How does this analysis shed new light on the findings of both DAPA and DELIVER?
-How should the results of this study be applied to clinical practice?
-What further study is needed?
Recorded on-site at HFA 23 in Prague.
Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on Twitter: / radcliffecardio - วิทยาศาสตร์และเทคโนโลยี
